🇺🇸 FDA
Patent

US 9120813

Oxadiazoanthracene compounds for the treatment of diabetes

granted A61PA61P1/12A61P1/16

Quick answer

US patent 9120813 (Oxadiazoanthracene compounds for the treatment of diabetes) held by VTV THERAPEUTICS LLC expires Mon Aug 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VTV THERAPEUTICS LLC
Grant date
Tue Sep 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61P, A61P1/12, A61P1/16, A61P13/12, A61P25/02